Weight Loss

Fake weight-loss pills, IVF funding gaps and what HRT may mean for brain health

GLP-1 and healthtech round-up

Fast-growing health markets are now facing a trust test.

Counterfeit weight-loss medicines, shrinking NHS fertility funding and fresh menopause research all point to the same problem: patients need clearer, safer ways to compare care before paying privately.

The week in brief

This week's health news is less about shiny launches and more about what happens when fast-moving treatment markets mature. MPs are warning that counterfeit weight-loss pills may be easier to produce and harder for patients to spot than fake injectable pens. New HFEA figures show UK IVF outcomes improving while the share of NHS-funded cycles keeps falling. And Cambridge-led research into menopause, HRT and brain health is a useful reminder that big studies need careful reading, especially when headlines move faster than the evidence.

For Health Compare Hub readers, the practical thread is simple: compare providers, check clinical safeguards, and be cautious when a treatment route looks unusually cheap, unusually easy, or too definite for the evidence.

In this round-up

Top stories

MPs warn the UK may struggle to keep pace with counterfeit weight-loss pills

Layla Moran, chair of the Health and Social Care Committee, has warned that the UK's medicines regulator may not have the resources needed to tackle a growing black market in counterfeit weight-loss medicines. The concern has sharpened since the approval of oral semaglutide for weight management, because tablets may be easier to counterfeit and distribute than injectable pens.

Parliamentary evidence heard in June pointed to the scale of the illegal medicines problem, including large seizures of counterfeit or unlicensed products. Clinicians have also warned that some fake injectable pens have contained substances such as insulin rather than semaglutide, which can be dangerous for people who do not have diabetes.

What this means for you

Only use a registered UK pharmacy or a provider that carries out a proper clinical consultation, asks about your medical history and explains follow-up. If a provider sells prescription weight-loss medication without checks, or the price looks far below the rest of the market, treat that as a safety warning rather than a bargain.

IVF outcomes are improving, but NHS-funded access keeps narrowing

The HFEA's 2024 figures show that around 53,000 patients had IVF at licensed UK clinics, with more than 21,000 babies born from IVF that year. IVF births now account for around 1 in 31 UK births, more than double the share seen in 2004.

Success rates have also improved. The average IVF birth rate per embryo transferred was 30% in 2024, up from 20% in 2014, although outcomes still vary by age, ethnicity and family type.

The access picture is moving in the other direction. NHS-funded IVF cycles fell from 35% of all IVF cycles in 2019 to 28% in 2024 across the UK, and were lowest in England at 25%. That leaves more patients comparing private fertility clinics, package prices and success-rate reporting on their own.

30%
Average birth rate per embryo transferred in 2024
28%
UK IVF cycles funded by the NHS in 2024
1 in 31
UK births from IVF in 2024
What this means for you

Do not assume NHS funding is available, especially in England where local Integrated Care Board criteria matter. If you are comparing private clinics, look beyond the headline cycle price: age-specific success rates, what is included, medication costs and refund-package terms can all change the real comparison.

What a major UK study says, and does not say, about menopause, HRT and the brain

A Cambridge-led analysis of UK Biobank data from nearly 125,000 women looked at associations between menopause, hormone replacement therapy, mental health, cognition and brain structure. It found links between menopause and changes in mental health, sleep, cognition and grey matter volume in specific brain regions.

The findings are important, but they need careful interpretation. The study is observational, so it can show associations but cannot prove that HRT causes a specific brain or mood outcome. Women using HRT may also be more likely to have had menopause symptoms that prompted treatment in the first place.

What this means for you

This is not a reason to stop or avoid HRT based on a headline. If you are taking HRT and have concerns about mood, sleep, memory or side effects, speak to your GP or menopause specialist before making changes.

Provider and market news

Beyond weight loss: hair loss, ED, TRT and blood testing

What is moving in the rest of digital health this week

  • Hair loss: recent UK coverage has highlighted specialist NHS dermatology work and clinical trials at Guy's and St Thomas', keeping alopecia and pattern hair-loss research in the public eye.
  • ED: private men's health clinics are continuing to package erectile dysfunction consultations alongside broader hormone, cardiovascular and lifestyle checks.
  • TRT: low diagnosis rates and long NHS routes continue to push demand toward private testosterone clinics, but pricing is hard to compare because medication, blood tests and monitoring may be billed separately.
  • Blood testing: NHS England is exploring self-sampling routes connected to digital health checks, while private at-home venous and finger-prick testing providers continue to expand.
What to watch Expect more clinics to bundle hormone testing into weight-loss, men's health and longevity packages. That can be useful, but it should be clinically justified rather than simply added because it increases order value.

Market and investment

Funding and regulatory moves shaping UK digital health

  • UK startup funding trackers continue to show strong investor interest in AI, healthtech and cyber security, with healthcare software still attracting capital even when consumer health brands face more scrutiny.
  • Diagnostics: startups working on less invasive testing, including breath-based diagnostics, are still raising funds as investors look for scalable alternatives to traditional lab pathways.
  • Regulation: the MHRA's work on international reliance routes could make it faster for some medical device and software products with trusted overseas approvals to reach the UK market.
What to watch Faster approval routes may bring useful tools to UK patients sooner, but comparison pages will need to explain what each product is approved for, who regulates it and whether it is a screening, monitoring or diagnostic tool.

Compare weight-loss providers side by side

Check current prices, consultation safeguards, treatment options and support signals across UK weight-loss providers.

Medical disclaimer

This article is for general information only and is not medical advice. Prescription medicines, fertility treatment and HRT decisions should always be discussed with a qualified healthcare professional.

Check out these articles

GuideCompetitor promo and pricing round-up: week commencing 27 July 2026

Current discount codes, first-order offers and headline prices across oral Wegovy, weight loss, ED, blood tests, ha...

Read more
Weight LossThe weight-loss pill era begins: oral Wegovy hits UK pharmacy shelves

Oral Wegovy launches in UK pharmacies, NICE opens its review of orforglipron, and the numbers behind Britain's GLP-...

Read more
GuideCompetitor promo and pricing round-up: week commencing 20 July 2026

This week's discount codes and headline prices across oral Wegovy, weight loss, ED, blood tests, hair loss and TRT...

Read more